Author

Miru Tang

Guangzhou Laboratory

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biophysics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:graph neural network· 1 Organism:mouse· 1

Frequent Co-Authors

Jinsai ShangiD· 4 shared Yongzhi LuiD· 4 shared Hongming CheniD· 3 shared Ting RaniD· 3 shared Anqi ZhouiD· 2 shared Bao Xue· 2 shared Jie Zheng· 2 shared Jielin TangiD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

Jinsai ShangORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

FXR-mediated recruitment of PPP1CB suppresses SMAD2/3 phosphorylation to mitigate pulmonary fibrosis

Wenqi Li, Qiong Wu, Yongzhi Lu, Xiaoqin Li, Lei Miao, Xia Y, Xianjie Qiu, Miru Tang, Z Y Li, Yang Peng, Wenxiang Hu, Wei Kevin Zhang, Jie Zheng, Cong Ma, Jinsai Shang

This study identifies FXR as a suppressor of pulmonary fibrosis by interacting with PPP1CB to reduce SMAD2/3 phosphorylation, showing therapeutic potential with TERN101.

bioRxiv · Jul 24, 2026 · PreprintCell Biology

A novel AR molecular glue degrader via bivalent engagement of the N-terminal domain and RNF213-UBE2J2 complex

Kunzhong Wu, Qiong Wu, Yongzhi Lu, Qi Yang, Ting Ran, Jie Zhang, Xianjie Qiu, Chengjie Huang, Yue Lin, J K Chen, Z L Yang, Wei Qin, Zhu Liu, Xinqi Liu, Miru Tang, , Jinsai Shang

This paper introduces GZL626, a novel AR degrader that targets the N-terminal domain and RNF213-UBE2J2 complex, effectively degrading AR and AR-V7 and showing antitumor and antiviral activity.

bioRxiv · Jul 16, 2026 · PreprintBiophysics

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Yongzhi Lu, Qi Yang, Ting Ran, Guihua Zhang, Weifeng Li, Peiqi Zhou, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, Jiayi Chen, Jiyun Zhang, , Jinsai Shang

The paper identifies a potent orally bioavailable SARS-CoV-2 PLpro inhibitor with in vitro and in vivo antiviral activity against SARS-CoV-2 and related coronaviruses.

Nature Communications · Nov 23, 2024Peer-reviewedMicrobiology

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

Yongzhi Lu, Ting Ran, Qi Yang, Guihua Zhang, Jiayi Chen, Peiqi Zhou, Wenqi Li, Minyuan Xu, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, , Jinsai Shang

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

bioRxiv · Sep 7, 2024 · PreprintMicrobiology